DC

Dishman Carbogen Amcis LtdNSE DCAL Stock Report

Last reporting period 31 Mar, 2024

Updated 17 Sep, 2024

Last price

Market cap $B

0.324

Micro

Exchange

XNSE - National Stock Exchange Of India

DCAL.NS Stock Analysis

DC

Uncovered

Dishman Carbogen Amcis Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

4/100

Low score

Market cap $B

0.324

Dividend yield

0.11 %

Shares outstanding

156.78 B

Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat and currently employs 1,295 full-time employees. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.

View Section: Eyestock Rating